Literature DB >> 24445188

BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.

Olga L Bohn1, Katharine Hsu2, David M Hyman2, Daniela S Pignataro1, Sergio Giralt2, Julie Teruya-Feldstein3.   

Abstract

Entities:  

Keywords:  BRAF mutation; Multiple myeloma; Refractory; Relapse; Vemurafenib

Mesh：

Substances：

Year:  2013        PMID： 24445188     DOI： 10.1016/j.clml.2013.12.003

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  9 in total

Review 1.  Toward personalized treatment in multiple myeloma based on molecular characteristics.

Authors:  Charlotte Pawlyn; Faith E Davies
Journal:  Blood       Date:  2018-12-26       Impact factor: 22.113

2.  Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.

Authors:  Bo-Jung Chen; Chang-Tsu Yuan; Ching-Fen Yang; Chung-Han Ho; Yen-Kuang Lin; Ying-Zhen Su; Hsiu-Chu Chou; Shih-Sung Chuang
Journal:  Virchows Arch       Date:  2022-06-03       Impact factor: 4.535

3.  MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32).

Authors:  Nicoletta Coccaro; Giuseppina Tota; Luisa Anelli; Antonella Zagaria; Paola Casieri; Angelo Cellamare; Crescenzio Francesco Minervini; Angela Minervini; Cosimo Cumbo; Luciana Impera; Claudia Brunetti; Paola Orsini; Elisa Parciante; Anna Mestice; Giorgina Specchia; Francesco Albano
Journal:  Oncol Lett       Date:  2016-06-22       Impact factor: 2.967

Review 4.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

5.  BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.

Authors:  E H Rustad; H Y Dai; H Hov; E Coward; V Beisvag; O Myklebost; E Hovig; S Nakken; D Vodák; L A Meza-Zepeda; A K Sandvik; K F Wader; K Misund; A Sundan; H Aarset; A Waage
Journal:  Blood Cancer J       Date:  2015-03-20       Impact factor: 11.037

6.  Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.

Authors:  Marta Lionetti; Marzia Barbieri; Katia Todoerti; Luca Agnelli; Simona Marzorati; Sonia Fabris; Gabriella Ciceri; Serena Galletti; Giulia Milesi; Martina Manzoni; Mara Mazzoni; Angela Greco; Giovanni Tonon; Pellegrino Musto; Luca Baldini; Antonino Neri
Journal:  Oncotarget       Date:  2015-09-15

7.  Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.

Authors:  Julia Garcia-Reyero; Nerea Martinez Magunacelaya; Sonia Gonzalez de Villambrosia; Sanam Loghavi; Angela Gomez Mediavilla; Raul Tonda; Sergi Beltran; Marta Gut; Ainara Pereña Gonzalez; Emanuele d'Ámore; Carlo Visco; Joseph D Khoury; Santiago Montes-Moreno
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

Review 8.  KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.

Authors:  Elena Vendramini; Riccardo Bomben; Federico Pozzo; Tamara Bittolo; Erika Tissino; Valter Gattei; Antonella Zucchetto
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

Review 9.  Liquid biopsies for multiple myeloma in a time of precision medicine.

Authors:  Bruna Ferreira; Joana Caetano; Filipa Barahona; Raquel Lopes; Emilie Carneiro; Bruno Costa-Silva; Cristina João
Journal:  J Mol Med (Berl)       Date:  2020-04-04       Impact factor: 4.599
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.